<DOC>
	<DOCNO>NCT01644617</DOCNO>
	<brief_summary>The purpose study evaluate dose-related effectiveness , safety tolerability MK-8237 , compare placebo , treatment house dust mite ( HDM ) -induced allergic rhinitis/rhinoconjunctivitis adult . The primary hypothesis administration MK-8237 , compare placebo , result dose-related improvement average total nasal symptom score ( TNSS ) determine environmental exposure chamber ( EEC ) challenge .</brief_summary>
	<brief_title>A Dose-Ranging Study Safety Effectiveness MK-8237 Treatment House Dust Mite ( HDM ) Induced Allergic Rhinitis/Rhinoconjunctivitis Adults ( MK-8237-003/P07627 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>History allergic rhinitis/rhinoconjunctivitis house dust 1 year duration ( without asthma ) If female childbearing potential , negative urine pregnancy test screening agree remain abstinent use ( partner use ) 2 acceptable method birth control within project duration study . Sensitized regularly expose animal dander mold , ( e.g . present home , job , etc . ) Sensitized regularly expose seasonal allergen ( i.e. , birch grass pollen ) Immunosuppressive treatment within 3 month prior screen ( except steroid allergic asthma symptom ) History chronic urticaria and/or angioedema within 2 year prior screen Previous immunotherapy treatment HDM allergen 1 month within 3 year prior screen Ongoing treatment specific immunotherapy History anaphylaxis cardiorespiratory symptom prior immunotherapy , due unknown cause inhalant allergen Unstable uncontrolled/partially control severe asthma , lifethreatening asthma attack occurrence clinical deterioration asthma result emergency treatment , hospitalization due asthma , treatment systemic corticosteroid ( allow shortacting beta agonist [ SABA ] ) within 3 month prior screen Asthma require medium highdose inhale corticosteroid ( ICS ) within 12 month prior screen Chronic sinusitis within 2 year prior screen Nasal condition could confound efficacy safety assessment ( e.g. , nasal polyp ) Pregnant , breastfeed plan become pregnant study Participation different investigational study site time frame study Direct association administration study family member study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>